Outpatient parenteral antimicrobial therapy (OPAT) from an emergency model applied during the COVID-19 pandemic to standard of care: Preliminary lessons from our experience - 05/03/23

Doi : 10.1016/j.idnow.2023.01.002

G. Giuliano ^a,^⁎ , F. Raffaelli ^a, D. Faliero ^a, E. Tamburrini ^a,^b, D. Tarantino ^c, M.C. Nurchis ^d, G. Scoppettuolo ^a
^a UOC Malattie Infettive, Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
^b Sezione Malattie Infettive, Dipartimento di sicurezza e bioetica, Università Cattolica del Sacro Cuore, Roma, Italy
^c UOC Farmacia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
^d UOC Igiene Ospedaliera, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy

^⁎Corresponding author at: Unità Operativa Complessa di Clinica delle Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, L.go Agostino Gemelli 8, 00168 Roma, Italy.Unità Operativa Complessa di Clinica delle Malattie InfettiveFondazione Policlinico Universitario Agostino Gemelli IRCCSL.go Agostino Gemelli 800168 RomaItaly

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Highlights

•	The COVID19 pandemic exerted unusual pressure on hospital systems.
•	The OPAT model enabled patients suffering from different infectious diseases to be treated as outpatients.
•	The strength of the OPAT model resides in its multidisciplinarity.
•	Infusion of antibiotics through elastomeric pumps effectively reduces carbapenem use.

Le texte complet de cet article est disponible en PDF.

Abstract

Objectives

We wish to report on our experience of OPAT during the first two years of the COVID19 outbreak.

Patients and methods

We recorded data on all patients treated in the OPAT regimen in 2020 and 2021 and compared overall trends, use of carbapenems and saved days of hospitalization.

Results

The OPAT model enabled us to ensure the administration of first choice antibiotic therapy to 239 patients with an increase of 21.3% from 2020 to 2021 (108 vs 131). Applying this model, we also recorded a reduction in the use of carbapenems from 33% in 2020 to 26% in 2021 and a total of 3041 recovery days saved in 2021.The clinical cure rate reached 94%. Few adverse events occurred (35/239; 14.6%), and they did not require hospitalization.

Conclusion

OPAT is a safe, efficacious, and cost-effective model that functioned effectively during the COVID-19 crisis and could become the standard of care for the treatment of selected patients.

Le texte complet de cet article est disponible en PDF.

Keywords : Antibiotics, Antimicrobial stewardship, Carbapenems, MDR, OPAT

Plan

Ethical approval

CRediT authorship contribution statement

Export

Vol 53 - N° 2

Article 104642- mars 2023 Retour au numéro

Article précédent

Knowledge on human papillomavirus (HPV), HPV screening and HPV vaccine among sexual health clinic patients in Martinique, French West Indies
O. Cabras, L. Sylvanise, A. Marquise, A. Cabié, L. Cuzin

| Article suivant

Recurrence of brucellosis on breast implants
C. Estagnasié, L. Surgers, K. Berdugo, L. Monnier-Cholley, M. Schmidt, J.-L. Meynard, E. Gras

Bienvenue sur EM-consulte, la référence des professionnels de santé.

connectez-vous ou créez un compte

Outpatient parenteral antimicrobial therapy (OPAT) from an emergency model applied during the COVID-19 pandemic to standard of care: Preliminary lessons from our experience - 05/03/23

Highlights

Abstract

Objectives

Patients and methods

Results

Conclusion

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL